Bots, editor, reviewer, Administrators
13,951
edits
Feed:All articles/Pretty: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
No edit summary |
||
| Line 973: | Line 973: | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2025- | "timestamp" : "2025-06-05T17:23:41Z", | ||
"briefDesignDescription" : "HbA1c and CKD risk in DM", | "briefDesignDescription" : "HbA1c and CKD risk in DM", | ||
"fulltexturl" : "http://archinte.jamanetwork.com/article.aspx?articleid", | "fulltexturl" : "http://archinte.jamanetwork.com/article.aspx?articleid", | ||
| Line 985: | Line 985: | ||
"briefResultsDescription" : "Elevated HbA1c increases risk of CKD", | "briefResultsDescription" : "Elevated HbA1c increases risk of CKD", | ||
"published" : "2008-12-08", | "published" : "2008-12-08", | ||
"pageName" : "ARIC", | "pageName" : "ARIC A1c and CKD", | ||
"diseases" : "Diabetes Mellitus;Diabetic Nephropathy", | "diseases" : "Diabetes Mellitus;Diabetic Nephropathy", | ||
"abbreviation" : "ARIC", | "abbreviation" : "ARIC", | ||
| Line 1,619: | Line 1,619: | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2025-06-05T17:40:19Z", | ||
"briefDesignDescription" : "Intensive BP control in DM", | "briefDesignDescription" : "Intensive BP control in DM", | ||
"fulltexturl" : "", | "fulltexturl" : "", | ||
| Line 1,632: | Line 1,632: | ||
"published" : "2024-11-16", | "published" : "2024-11-16", | ||
"pageName" : "BPROAD", | "pageName" : "BPROAD", | ||
"diseases" : " | "diseases" : "Diabetes Mellitus;Hypertension", | ||
"abbreviation" : "BPROAD", | "abbreviation" : "BPROAD", | ||
"title" : "Intensive blood-pressure control in patients with type 2 diabetes", | "title" : "Intensive blood-pressure control in patients with type 2 diabetes", | ||
| Line 4,032: | Line 4,032: | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2025- | "timestamp" : "2025-06-05T17:26:20Z", | ||
"briefDesignDescription" : "Lifestyle interventions to prevent diabetes", | "briefDesignDescription" : "Lifestyle interventions to prevent diabetes", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM200105033441801#t", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM200105033441801#t", | ||
| Line 6,367: | Line 6,367: | ||
"title" : "Oral versus Intravenous Antibiotics for Bone and Joint Infection", | "title" : "Oral versus Intravenous Antibiotics for Bone and Joint Infection", | ||
"pmid" : "30699315" | "pmid" : "30699315" | ||
}, | |||
{ | |||
"timestamp" : "2025-06-05T18:03:47Z", | |||
"briefDesignDescription" : "Durvalumab vs. placebo as consolidation in NSCLC", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1709937", | |||
"pageid" : 2969, | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1709937", | |||
"trainingLevel" : "Fellow", | |||
"citation" : "Antonia SJ <i>et al</i>. \"Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer\". <i>The New England Journal of Medicine</i>. 2017. 377(20):1919-1929.", | |||
"subspecialties" : "Oncology;Radiation Oncology", | |||
"expansion" : "", | |||
"statusUsableDate" : "2025-06-12", | |||
"briefResultsDescription" : "Durvalumab increases PFS in NSCLC", | |||
"published" : "2017-09-08", | |||
"pageName" : "PACIFIC", | |||
"diseases" : "Lung Cancer", | |||
"abbreviation" : "PACIFIC", | |||
"title" : "Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer", | |||
"pmid" : "28885881" | |||
}, | }, | ||
{ | { | ||